Ellie Leick

Articles

Neoadjuvant Chemo Leads to Encouraging Resection Rates in Pancreatic Adenocarcinoma

October 2nd 2019

Davendra Sohal, MD, MPH, discusses the SWOG S1505 data and other emerging areas of research in pancreatic cancer.

TAS-102 Becomes Promising Option in Chemorefractory Gastric/GEJ Cancers

September 27th 2019

David H. Ilson, MD, PhD, discusses the utility of TAS-102 in gastric and GEJ adenocarcinoma as well as other encouraging research in these spaces.

Combo Strategies, Sequencing Research Ongoing in EGFR-Mutant NSCLC

September 26th 2019

Raja Mudad, MD, FACP, discussed the available EGFR inhibitors and sequencing challenges for patients with EGFR-mutant non-small cell lung cancer.

Biomarkers Require Refining in Lung Cancer Paradigm

September 25th 2019

Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.

Treatment Options Are Expanding for Benign Hematologic Disorders

September 24th 2019

Kanwarpal S. Kahlon, MD, discusses current treatment options for patients with aplastic anemia, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura, as well as future research for the field.

Genetic Testing Throughout Disease Course Critical in Lung Cancer

September 24th 2019

Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

Genomics Are Key to Unlocking Breast Cancer Biology

September 23rd 2019

Paul Kelly Marcom, MD, discusses the role of genomic testing in breast cancer.

AML Research Focus Adapting to Address Heterogeneity

September 20th 2019

Gary J. Schiller, MD, discusses therapeutic advances, the importance of genomic testing, and other agents in the pipeline for acute myeloid leukemia.

Osimertinib Continues to Gain Momentum as Frontline Therapy in EGFR+ NSCLC

September 19th 2019

Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Intriguing Strategies Taking Shape in Mantle Cell Lymphoma

September 18th 2019

Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.

Treatment Options for ALK+ NSCLC Continue to Grow

September 16th 2019

Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.

Myelofibrosis Management Makes Strides With JAK Inhibitors, But Work Remains

September 15th 2019

Laura C. Michaelis, MD, discusses the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Despite Challenges, Targeted Cellular Therapies Continue to Be Explored in AML

September 13th 2019

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

JAK Inhibition Continues to Push Progress in Myelofibrosis

September 13th 2019

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Immunotherapy Biomarker Hunt Continues in Lung Cancer

September 11th 2019

Robert A. Kratzke, MD discusses the excitement surrounding immunotherapy and the work being done with biomarkers to assist in making optimal treatment decisions in lung cancer.

Expert Highlights Next Steps With Chemoimmunotherapy in Nonsquamous NSCLC

September 5th 2019

Manish Patel, DO, discusses advances and remaining questions with chemoimmunotherapy combinations in nonsquamous metastatic non–small cell lung cancer.

Encouraging Data Advance Research in Relapsed/Refractory Myeloma

September 5th 2019

Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.

Challenges Remain, But Research Abounds in Polycythemia Vera and Myelofibrosis

September 3rd 2019

David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefit in BRAF-Mutant Melanoma

September 3rd 2019

Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.

Genomic Testing Puts Myeloma Paradigm on Personalized Path

August 30th 2019

Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.